Payment overview · 2025
General Payments
$131.98
6 reported records · 4 companies
Healthcare provider profile · identity verified
Dalia Youssef, MD
Allopathic & Osteopathic Physicians|Family Medicine · ASHLAND, OH · NPI 1215459326
Verified facts
What the public records show
CMS Open Payments records show Dalia Youssef, MD received $131.98 in general payments during 2025 across 6 reported records.
Exact Sciences Corporation accounted for 43.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.95 | 43.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.12 | 32.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.95 | 12.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.96 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.98 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 84 |
| Losartan Potassium | Losartan Potassium | 310 | 72 |
| Lisinopril | Lisinopril | 265 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 58 |
| Omeprazole | Omeprazole | 196 | 55 |
| Gabapentin | Gabapentin | 183 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 45 |
| Carvedilol | Carvedilol | 148 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 34 |
| Meloxicam | Meloxicam | 116 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 28 |
| Famotidine | Famotidine | 106 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 26 |
| Furosemide | Furosemide | 101 | 33 |
| Ezetimibe | Ezetimibe | 87 | 25 |
| Metformin Hcl Er | Metformin Hcl | 85 | 25 |
| Alendronate Sodium | Alendronate Sodium | 83 | 17 |
| Sertraline Hcl | Sertraline Hcl | 83 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 15 |
| Montelukast Sodium | Montelukast Sodium | 70 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 11 |
| Allopurinol | Allopurinol | 64 | 17 |
| Ozempic | Semaglutide | 64 | 15 |
| Potassium Chloride | Potassium Chloride | 63 | 19 |
| Eliquis | Apixaban | 62 | 15 |
| Glimepiride | Glimepiride | 61 | 15 |
| Mirtazapine | Mirtazapine | 60 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 16 |
| Simvastatin | Simvastatin | 51 | 13 |
| Trazodone Hcl | Trazodone Hcl | 47 | 11 |
| Bupropion Xl | Bupropion Hcl | 46 | 17 |
| Jardiance | Empagliflozin | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Metformin Hcl | Metformin Hcl | 41 | 14 |
| Atenolol | Atenolol | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 11 |
| Prednisone | Prednisone | 35 | 28 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | 12 |
| Linzess | Linaclotide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.98 · 6 records | Exact Sciences Corporation | Cologuard Collection Kit, Dexcom G6 Transmitter, QULIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error